ClinicalTrials.Veeva

Menu

The Evaluation of Lung Cancer Patient Treated With Epidermal Growth Factor Receptor Tyrosine Kinase (EVALUATE)

D

Dr. Soetomo General Hospital

Status

Unknown

Conditions

Non-Small-Cell Lung Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT02755337
Dr. Soetomo General Hospital

Details and patient eligibility

About

To evaluate Non-Small Cell Lung Cancer (NSCLC) patients clinical profile and the outcome after treatment with Gefitinib in Pulmonary Oncology Outpatient Clinic Dr. Soetomo General Hospital, Surabaya, Indonesia.

Full description

Primary Objective: To determine the efficacy of Gefitinib in NSCLC patient harboring a positive EGFR mutation.

Secondary Objective: To evaluate the subjective response of NSCLC patients harboring a positive EGFR mutation who treated with Gefitinib.

Safety Objective: To evaluate the safety and tolerability of Gefitinib in NSCLC patient harboring a positive EGFR mutation.

Enrollment

70 estimated patients

Sex

All

Ages

16 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • NSCLC based on histopathologic examination
  • Adenocarcinoma and/or nonadenocarcinoma based on histology examination
  • Clinical stadium stage IIIB and IV
  • Age 16-70 years old
  • Received gefitinib as therapy
  • At least completed 2 (two) data sets of RECIST 1.1 evaluations during the study period from January 2013 until July 2015

Exclusion criteria

  • Missing data of any variables of the treatment outcomes in the medical record

Trial contacts and locations

1

Loading...

Central trial contact

Laksmi Wulandari, MD, PhD; Anna Febriani, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems